Metformin in reproductive health, pregnancy and gynaecological cancer: Established and emerging indications

Human Reproduction Update

Volumn 20, Issue 6, 2014, Pages 853-868

  Sivalingam, Vanitha N ^a   Myers, Jenny ^a   Nicholas, Susie ^b   Balen, Adam H ^b   Crosbie, Emma J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SEACROFT HOSPITAL   (United Kingdom)

Author keywords

Endometrial cancer; Gestational diabetes; Metformin; Obesity in pregnancy; Polycystic ovary syndrome

Indexed keywords

CLOMIFENE CITRATE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; ANTIDIABETIC AGENT; CLOMIFENE;

ACNE; ANOVULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIRTH RATE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDICATION; DRUG SAFETY; EMBRYO TRANSFER; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; GYNECOLOGIC CANCER; HIRSUTISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; INTRACYTOPLASMIC SPERM INJECTION; LIFESTYLE MODIFICATION; LIVE BIRTH; MATERNAL OBESITY; MEDLINE; META ANALYSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OFF LABEL DRUG USE; OVARY CANCER; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; OXIDATIVE STRESS; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; PREGNANT WOMAN; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE HEALTH; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; WEIGHT GAIN; DIABETES, GESTATIONAL; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; LIFESTYLE; OVULATION INDUCTION; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PREGNANCY OUTCOME; PREGNANCY RATE;

CLOMIPHENE; DIABETES, GESTATIONAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; METFORMIN; OVULATION; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; REPRODUCTIVE HEALTH;

EID: 84913526342     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmu037     Document Type: Article

References (149)

1. Ainge H, Thompson C, Ozanne SE, Rooney KB. A systematic reviewon animal models of maternal high fat feeding and offspring glycaemic control. Int J Obes (Lond) 2011; 35:325-335.
2. Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli L, Birman E, Viollett B, Ferbeyre G, Pollak M. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res 2012;5:536-543.
3. Ali AT, FerrisWF, Naran NH, Crowther NJ. Insulin resistance in the control of body fat distribution: a new hypothesis. Horm Metab Res 2011;43:77-80.
4. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-524.
5. Bailey C, Campbell I, Chan J, Davidson J, Howlett H, Ritz P. Metformin-the Gold Standard: Scientific Handbook. UK: Wiley (Chichester), 2008.
6. Balani J, Hyer SL, RodinDA, Shehata H. Pregnancy outcomes inwomenwith gestational diabetes treated with metformin or insulin: a case-control study. Diabet Med 2009; 26:798-802.
7. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol 2013;373:77-82.
8. Balen AH, Anderson RA. Impact of obesityon female reproductive health: British Fertility Society, Policy and Practice Guidelines. Hum Fertil (Camb) 2007;10:195-206.
9. Balen AH, Dresner M, Scott EM, Drife JO. Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ 2006;332:434-435.
10. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care 2007;30(Suppl 2):S112-S119.
11. Beck P, Daughaday WH. Human placental lactogen: studies of its acute metabolic effects and disposition in normal man. J Clin Invest 1967;46:103-110.
12. Becker C, Jick SS, Meier CR, Bodmer M. Metformin and the risk of endometrial cancer: a case-control analysis. Gynecol Oncol 2013;129:565-569.
13. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti J, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-3586.
14. BenSahra I,RegazzettiC,RobertG,Laurent K,LeMarchand-BrustelY,AubergerP,Tanti JF, Giorgetti-Peraldi S, Bost F.Metformin, independent of AMPK, inducesmTORinhibition and cell-cycle arrest through REDD1. Cancer Res 2011;71:4366-4372.
15. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril 1993;59:323-331.
16. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011;123:200-204.
17. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca M, Galimberti V, Veronesi P et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012; 30:2593-2600.
18. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673-683.
19. Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 2008;89:1039-1048.
20. Brewer C, Acharya S, Thake F, TangT, Balen A. Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. Hum Fertil (Camb) 2010;13:134-142.
21. Brown KA, Hunger NI, Docanto M, Simpson ER. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010;123:591-596.
22. Buchanan TA, Metzger BE, Freinkel N, Bergman RN. Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes. Am J Obstet Gynecol 1990;162:1008-1014.
23. Burzawa J, Schmeler K, Soliman P, Meyer L, Bevers M, Pustilnik T, Anderson M, Ramondetta L, Tortolero-Luna G, Urbauer D et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol 2011; 204:e1-e7.
24. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-98.
25. Catalano PM, Tyzbir ED, RomanNM,Amini SB, Sims EA. Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. Am J Obstet Gynecol 1991;165:1667-1672.
26. Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003;133:1674S-1683S.
27. Cazzaniga M, Decensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'orto P et al. The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 2013; 109:2792-2797
28. Chang RJ, Cook-Andersen H. Disordered follicle development. Mol Cell Endocrinol 2013;373:51-60.
29. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-1597.
30. Clark AM, LedgerW, Galletly C, Tomlinson L, Blaney F,Wang X, Norman RJ.Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-2712.
31. Coetzee EJ, Jackson WP. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979;16:241-245.
32. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007;CD005552.
33. Crosbie EJ, Zwahlen M, Kitchener H, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:3119-3130.
34. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-2358.
35. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, Chaudhuri A. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043-5047.
36. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 2010;3:1451-1461.
37. De Leo V, La Marca A, Orvieto R, Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1598-1600.
38. Desai N, Roman A, Rochelson B, Gupta M, Xue X, Chatterjee PK, Tam Tam H, Metz CN. Maternal metformin treatment decreases fetal inflammation in a rat model of obesity and metabolic syndrome. Am J Obstet Gynecol 2013;209:136 e131-139.
39. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162:193-212.
40. Dornan T, Hollis S. Critical appraisal of published research evidence: treatment of gestational diabetes. Diabet Med 2001;(Suppl 3):1-5.
41. DowsettM, Smith IE, Ebbs SR,Dixon JM, Skene A, A'Hern R, Salter J,Detre S,HillsM, Walsh G. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99: 167-170.
42. EHSRE/ASRM TEA-SPCWG. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-522.
43. Ekpebegh CO, Coetzee EJ, van der Merwe L, Levitt NS. A 10-year retrospective analysis of pregnancy outcome in pregestational Type 2 diabetes: comparison of insulin and oral glucose-lowering agents. Diabet Med 2007;24:253-258.
44. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000;275:223-228.
45. Erdemoglu E, Guney M, Giray SG, Take G, Mungan T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2009;145:195-199.
46. ESHRE/ASRM REASPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
47. Evans J, Donnelly L, Emslie-Smith A, Alessi D, Morris A. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.
48. Fauser BC, Tarlatzis BC, RebarRW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS ConsensusWorkshop Group. Fertil Steril 2012;97:28-38 e25.
49. Fedorcsak P, Dale PO, Storeng R, Tanbo T, Abyholm T. The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum Reprod 2001;16:1086-1091.
50. Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, Haddad N, Yakar S, LeRoith D. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer 2013; 20:391-401.
51. Friberg E, Orsini N, Mantzoros C,Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365-1374.
52. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850.
53. Galtier-Dereure F, Boegner C, Bringer J. Obesity and pregnancy: complications and cost. Am J Clin Nutr 2000;71:1242S-1248S.
54. Gandhi P, Bustani R, Madhuvrata P, Farrell T. Introduction of metformin for gestational diabetes mellitus in clinical practice: has it had an impact? Eur J Obstet Gynecol Reprod Biol 2012;160:147-150.
55. Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. Diabet Med 2011;28:1082-1087.
56. Goodwin P, Stambolic V, Lemieux J, Chen B, ParulekarW, Gelmon K, Hershman D, Hobday T, Ligibel J, Mayer I et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 2011;126:215-220.
57. Hadad S, IwamotoT, Jordan L, PurdieC, Bray S, Baker L, Jellema G,Deharo S, Hardie D, Pusztai L et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 2011;128:783-794.
58. Hague WM, Davoren PM, Oliver J, Rowan J. Contraindications to use of metformin. Metformin may be useful in gestational diabetes. BMJ 2003;326:762; author reply 762.
59. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
60. Handwerger S, Freemark M. The roles of placental growth hormone and placental lactogen in the regulation of human fetal growth and development. J Pediatr Endocrinol Metab 2000;13:343-356.
61. Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 2012; 125:458-469.
62. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006;47:1183-1188.
63. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-7511.
64. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-2593.
65. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.
66. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J et al. Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther 2013;12:2847-2856.
67. Ijas H, Vaarasmaki M, Morin-Papunen L, Keravuo R, Ebeling T, SaarelaT, RaudaskoskiT. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG 2011;118:880-885.
68. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596.
69. Isoda K, Young J, Zirlik A, MacFarlane L, Tsuboi N, Gerdes N, Schonbeck U, Libby P. Metformin inhibits proinflammatory responses and nuclear factorkappa B in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26:611-617.
70. Jiralerspong S, Palla S, Giordano S, Meric-Bernstam F, Liedtke C, Barnett C, Hsu L, Hung M, Horotbagyi G, Gonzalez-Angulo A. Metformin and pathologic complete response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-3302.
71. Joly DJ, Lilienfeld AM, Diamond EL, Bross ID.An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am J Epidemiol 1974; 99:190-209.
72. Joshua A, Zannella V, Downes M, Bowes B, Koritzinsky M, Sweet J, Trachtenberg J, Jewett M, Finelli A, Fieshner N et al. Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma. In American Society of Clinical Oncology, 2013; 5070.
73. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010;11:390-401.
74. Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI inwomen with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod 2004;19:1315-1322.
75. Kjotrod SB, Carlsen SM, Rasmussen PE, Holst-Larsen T, Mellembakken J, Thurin-Kjellberg A, Haapaniemikouru K, Morin-Papunen L, Humaidan P, Sunde A et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod 2011; 26:2045-2053.
76. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
77. Ko EM,Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2013;132:438-442.
78. Kuhl C. Etiology and pathogenesis of gestational diabetes. Diabetes Care 1998; 21(Suppl 2):B19-B26.
79. Kumar S, Meuter A, Thapa P, LangstraatC, Giri S, Chien J, Rattan R, ClibyW, ShridharV. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013;119:555-562.
80. Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab 2000;2:131-137.
81. Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism 2013;62:1522-1534.
82. Lebovitz H. Insulin resistance: definitions and consequences. Exp Clin Endocrinol Diabetes 2001;109:S135-S148.
83. Lee JY, Jeon I, KimJW, Song YS, YoonJM, Park SM. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer 2013;23:402-412.
84. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-566.
85. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13:376-388.
86. Liao H, Zhou Q, Gu Y, Duan T, Feng Y. Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep 2012;27:1873-1878.
87. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-1625.
88. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009;29:172-182.
89. Lucenteforte E, Bosetti C, Talamini R, Montella M, Zucchetto A, Pelucchi C, Franceschi S, Negri E, Levi F, La Vecchia C. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer 2007;97:995-998.
90. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 1997;244:1-14.
91. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006;332:1485.
92. Moran LJ, Missi ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010;16:347-363.
93. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippelainen M, Perheentupa A, Tinkanen H, Bloigu R, Puukka K, Ruokonen A et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012;97:1492-1500.
94. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009;10:5-13.
95. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:621-629.
96. Nastri CO, Ferriani RA, Rocha IA, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 2010;27:121-128.
97. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
98. Nerstedt A, Johansson A, Andersson CX, Cansby E, Smith U, Mahlapuu M. AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3 (STAT3). Diabetologia 2010;53:2406-2416.
99. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623.
100. Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Frimer M, Conroy E, Goldberg GL, Einstein MH. Metformin use and endometrial cancer survival. Gynecol Oncol 2013;132:236-240.
101. Niraula S, Dowling R, Ennis M, Chang M, Done S, Hood N, Escallon J, Leong W, McCready D, Reedijk M et al. Metformin in early breast cancer: a prospective windowofopportunity neoadjuvant study. BreastCancerResTreat 2012;135:821-830.
102. Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. Diabetes Res Clin Pract 2012;98:422-429.
103. Oteng-Ntim E, Varma R, Croker H, Poston L, Doyle P. Lifestyle interventions for overweight and obese pregnant women to improve pregnancy outcome: systematic review and meta-analysis. BMC Med 2012;10:47.
104. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348(Pt 3):607-614.
105. Palomba S, Falbo A, Orio F Jr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009;92:1646-1658.
106. Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-1383.
107. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer 2008;8:915-928.
108. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-169.
109. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-297.
110. Ramsay JE, Ferrell WR, Crawford L,Wallace AM, Greer IA, Sattar N. Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab 2002;87:4231-4237.
111. RCOG SG. Current Management of Polycystic Ovary Syndrome. London: RCOG Press, 2010.
112. Renehan A, Tyson M, Egger M, Heller R, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578.
113. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, Johnston DG, Franks S. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 1993; 39:351-355.
114. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002;11:822-828.
115. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ 2011;343:d6309.
116. Rowan JA, HagueWM,GaoW, Battin MR, MooreMP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-2015.
117. Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 2011;34:2279-2284.
118. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; CD002967.
119. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I,Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 2013;8:e61537.
120. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-7270.
121. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5:157-167.
122. Schuler K, Rambally B, DiFurio M, Gehrig P, Bae-Jump V. A pre-operative window study of metformin for the treatment of endometrial cancer. J Clin Oncol 2013;31: Abstract 5519.
123. Session D, Kalli K, Tummon I, Damario M, Dumesic D. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003; 17:405-407.
124. ShenZQ,ZhuHT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465-467.
125. Sivalingam V, Crosbie EJ. Endometrial cancer. In: Diapedia, Edition European Association for the Study of Diabetes, 2013; Diapedia 61044601112 rev.no.61044601124.
126. Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco RP. Randomized trial of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol 2013;209:34 e31-37.
127. Srividhya S, Ravichandran MK, Anuradha CV. Metformin attenuates blood lipid peroxidation and potentiates antioxidant defense in high fructose-fed rats. J Biochem Mol Biol Biophys 2002;6:379-385.
128. StadtmauerLA,Wong BC,Oehninger S. Should patientswith polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-beyond ovulation induction. Hum Reprod 2002;17:3016-3026.
129. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603.
130. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554.
131. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006a;21:80-89.
132. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006b;21:1416-1425.
133. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; 5:CD003053.
134. Tanvig M, Wehberg S, Vinter CA, Joergensen JS, Ovesen PG, Beck-Nielsen H, Jensen DM, Christesen HT. Pregestational body mass index is related to neonatal abdominal circumference at birth-a Danish population-based study. BJOG 2013; 120:320-330.
135. Tas M, Kutuk MS, Serin IS, Ozgun MT, Oner G, Ozturk F. Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol 2013;29:311-314.
136. Tertti K, Ekblad U, Vahlberg T, Ronnemaa T. Comparison of metformin and insulin in the treatment of gestational diabetes: a retrospective, case-control study. Rev Diabet Stud 2008;5:95-101.
137. Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab 2013;15:246-251.
138. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
139. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1-17.
140. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009; CD006105.
141. UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
142. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogoy K, Kleggetveit O, Hjelle S, von Brandis P, Eikeland T, Flo K et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010;95:E448-E455.
143. Wang Y, Zhu Y, Zhang L, Tian W, Hua S, Zhao J, Zhang H, Xue F. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett 2012;322:223-231.
144. XieY,Wang YL, Yu L,Hu Q, Ji L, Zhang Y, LiaoQP. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-120.
145. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009;91:514-521.
146. Zakikhani M, Dowling R, Fantus I, Sononberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269-10273.
147. Zakikhani M, Dowling R, Sonenberg N, Pollak M. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008;1:369-375.
148. Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010;123:271-279.
149. Zhu MJ, Du M, Nathanielsz PW, Ford SP. Maternal obesity up-regulates inflammatory signaling pathways and enhances cytokine expression in the mid-gestation sheep placenta. Placenta 2010;31:387-391.